Sarepta Therapeutics has appointed Michael Severino as its new CEO, effective immediately, succeeding Doug Ingram, who retired after nearly a decade. Severino previously led Tessera Therapeutics and held key positions at AbbVie, where he focused on R&D and corporate strategy. His appointment comes at a critical time as Sarepta seeks full FDA approvals for its Duchenne muscular dystrophy therapies, Amondys 45 and Vyondys 53, following failed confirmatory trials. Despite these challenges, analysts remain optimistic about the drugs’ potential as the FDA is expected to make a decision by February 2027.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/business/sarepta-names-former-abbvie-r-d-exec-michael-severino-as-next-ceo
